{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:32:34Z","timestamp":1777984354529,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fentanyl\u2019s penetration into the unregulated drug supply has complicated the treatment of opioid use disorder (OUD), particularly by increasing the risk of buprenorphine-precipitated opioid withdrawal (BPOW). Buprenorphine, a partial opioid agonist, remains a first-line treatment for OUD, but traditional induction methods can be intolerable for people using fentanyl. Low-dose induction (LDI), a strategy characterized by gradual buprenorphine titration without prior withdrawal, has emerged as a promising alternative to mitigate BPOW. However, the feasibility and acceptability of LDI in low-barrier, real-world settings such as syringe services programs (SSPs) remain underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a mixed-methods prospective cohort study from June 2023\u20132024 at an SSP in Miami, Florida, offering a 4-day LDI protocol to patients with OUD who were interested in starting buprenorphine. Follow-up, conducted on a walk-in basis within four weeks, included urine drug screens (UDS), symptom surveys and semi-structured qualitative interviews. The primary outcome was successful buprenorphine initiation, defined by a positive UDS for buprenorphine at follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 30 participants enrolled in the 4-day LDI protocol, most (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929) had prior buprenorphine experience and nearly 90% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) reported past BPOW. Only 16 (53%) returned for follow-up. Nine (56%) of those followed up tested positive for buprenorphine, 11 (68.8%) reported that LDI worked for them, and 12 (75%) said they would use the method again. Qualitative interviews revealed six key themes: (1) LDI mitigates withdrawal symptoms; (2) instructions were helpful but could be improved; (3) fear of BPOW motivated LDI use; (4) LDI enabled autonomy in recovery; (5) unstable living environments hindered adherence; and (6) LDI allowed participants to maintain social roles.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While only 30% of the cohort had objective evidence of buprenorphine induction, most reported successful attempts and found LDI acceptable and empowering. High loss to follow-up and environmental instability limited our conclusions in this outpatient harm reduction setting. Further research is needed to refine LDI protocols and address the structural determinants affecting treatment success among people who use fentanyl.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00661-7","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:37:25Z","timestamp":1775461045000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of low-dose buprenorphine induction at a syringe services program"],"prefix":"10.1186","volume":"21","author":[{"given":"Maia H.","family":"Hauschild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peyton V.","family":"Warp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Eger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bahamon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler S.","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa A.","family":"Chueng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina J.","family":"Ciraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Serota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"661_CR1","doi-asserted-by":"publisher","first-page":"103086","DOI":"10.1016\/j.drugpo.2020.103086","volume":"94","author":"P Reuter","year":"2021","unstructured":"Reuter P, Pardo B, Taylor J. Imagining a fentanyl future: some consequences of synthetic opioids replacing heroin. Int J Drug Policy Aug. 2021;94:103086. https:\/\/doi.org\/10.1016\/j.drugpo.2020.103086.","journal-title":"Int J Drug Policy Aug"},{"key":"661_CR2","unstructured":"CDC, National Center for Health Statistics. U.S. overdose deaths decrease almost 27% in 2025. https:\/\/www.cdc.gov\/ (2025). Accessed 14 May 2025."},{"issue":"2","key":"661_CR3","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"5","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open Feb. 2020;5(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open Feb"},{"issue":"9","key":"661_CR4","doi-asserted-by":"publisher","first-page":"e2435895","DOI":"10.1001\/jamanetworkopen.2024.35895","volume":"3","author":"AP Thakrar","year":"2024","unstructured":"Thakrar AP, Christine PJ, Siaw-Asamoah A, et al. Buprenorphine-precipitated withdrawal among hospitalized patients using fentanyl. JAMA Netw Open Sep. 2024;3(9):e2435895. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.35895.","journal-title":"JAMA Netw Open Sep"},{"issue":"3","key":"661_CR5","doi-asserted-by":"publisher","first-page":"e236108","DOI":"10.1001\/jamanetworkopen.2023.6108","volume":"1","author":"G D\u2019Onofrio","year":"2023","unstructured":"D\u2019Onofrio G, Hawk KF, Perrone J, et al. Incidence of precipitated withdrawal during a multisite emergency department-initiated buprenorphine clinical trial in the era of fentanyl. JAMA Netw Open Mar. 2023;1(3):e236108. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.6108.","journal-title":"JAMA Netw Open Mar"},{"issue":"5","key":"661_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/ADM.0000000000001185","volume":"17","author":"HE Bird","year":"2023","unstructured":"Bird HE, Huhn AS, Dunn KE, Fentanyl Absorption. Distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl. J Addict Med May. 2023;17(5):503\u20138. https:\/\/doi.org\/10.1097\/ADM.0000000000001185.","journal-title":"J Addict Med May"},{"issue":"3","key":"661_CR7","doi-asserted-by":"publisher","first-page":"e210477","DOI":"10.1001\/jamanetworkopen.2021.0477","volume":"1","author":"DR Fine","year":"2021","unstructured":"Fine DR, Lewis E, Weinstock K, Wright J, Gaeta JM, Baggett TP. Office-based addiction treatment retention and mortality among people experiencing homelessness. JAMA Netw Open Mar. 2021;1(3):e210477. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0477.","journal-title":"JAMA Netw Open Mar"},{"issue":"2S Suppl 1","key":"661_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","volume":"14","author":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder","year":"2020","unstructured":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. 2020 Focused Update. J Addict Med Mar\/Apr. 2020;14(2S Suppl 1):1\u201391. https:\/\/doi.org\/10.1097\/ADM.0000000000000633.","journal-title":"J Addict Med Mar\/Apr"},{"issue":"4","key":"661_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/ajad.13135","volume":"30","author":"S Ahmed","year":"2021","unstructured":"Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine\/naloxone: a review of the literature. Am J Addict Jul. 2021;30(4):305\u201315. https:\/\/doi.org\/10.1111\/ajad.13135.","journal-title":"Am J Addict Jul"},{"issue":"2","key":"661_CR10","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","volume":"01","author":"D Button","year":"2022","unstructured":"Button D, Hartley J, Robbins J, Levander XA, Smith NJ, Englander H. Low-dose buprenorphine initiation in hospitalized adults with opioid use disorder: a retrospective cohort analysis. J Addict Med Mar-Apr. 2022;01(2):e105\u201311. https:\/\/doi.org\/10.1097\/ADM.0000000000000864.","journal-title":"J Addict Med Mar-Apr"},{"issue":"5","key":"661_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/dar.13113","volume":"39","author":"R Brar","year":"2020","unstructured":"Brar R, Fairbairn N, Sutherland C, Nolan S. Use of a novel prescribing approach for the treatment of opioid use disorder: buprenorphine\/naloxone micro-dosing - a case series. Drug Alcohol Rev Jul. 2020;39(5):588\u201394. https:\/\/doi.org\/10.1111\/dar.13113.","journal-title":"Drug Alcohol Rev Jul"},{"issue":"1","key":"661_CR12","doi-asserted-by":"publisher","first-page":"e2456253","DOI":"10.1001\/jamanetworkopen.2024.56253","volume":"2","author":"LW Suen","year":"2025","unstructured":"Suen LW, Chiang AY, Jones BLH, et al. Outpatient low-dose initiation of buprenorphine for people using fentanyl. JAMA Netw Open Jan. 2025;2(1):e2456253. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.56253.","journal-title":"JAMA Netw Open Jan"},{"issue":"4","key":"661_CR13","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1097\/ADM.0000000000001133","volume":"01","author":"E Sokolski","year":"2023","unstructured":"Sokolski E, Skogrand E, Goff A, Englander H. Rapid low-dose buprenorphine initiation for hospitalized patients with opioid use disorder. J Addict Med Jul-Aug. 2023;01(4):e278\u201380. https:\/\/doi.org\/10.1097\/ADM.0000000000001133.","journal-title":"J Addict Med Jul-Aug"},{"issue":"1","key":"661_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13722-023-00392-z","volume":"1","author":"JP Murray","year":"2023","unstructured":"Murray JP, Pucci G, Weyer G, Ari M, Dickson S, Kerins A. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series. Addict Sci Clin Pract Jun. 2023;1(1):38. https:\/\/doi.org\/10.1186\/s13722-023-00392-z.","journal-title":"Addict Sci Clin Pract Jun"},{"issue":"7","key":"661_CR15","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2105\/AJPH.2020.305705","volume":"110","author":"MEC Ginoza","year":"2020","unstructured":"Ginoza MEC, Tomita-Barber J, Onugha J, et al. Student-run free clinic at a syringe services program, miami, florida, 2017\u20132019. Am J Public Health Jul. 2020;110(7):988\u201390. https:\/\/doi.org\/10.2105\/AJPH.2020.305705.","journal-title":"Am J Public Health Jul"},{"issue":"1","key":"661_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/07853890.2023.2182908","volume":"55","author":"E Suarez Jr","year":"2023","unstructured":"Suarez E Jr., Bartholomew TS, Plesons M, et al. Adaptation of the tele-harm reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study. Ann Med Dec. 2023;55(1):733\u201343. https:\/\/doi.org\/10.1080\/07853890.2023.2182908.","journal-title":"Ann Med Dec"},{"issue":"2","key":"661_CR17","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","volume":"38","author":"E Proctor","year":"2011","unstructured":"Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. Adm Policy Ment Health Mar. 2011;38(2):65\u201376. https:\/\/doi.org\/10.1007\/s10488-010-0319-7.","journal-title":"Adm Policy Ment Health Mar"},{"issue":"5","key":"661_CR18","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/ADM.0000000000000961","volume":"01","author":"LW Suen","year":"2022","unstructured":"Suen LW, Lee TG, Silva M, et al. Rapid overlap initiation protocol using low dose buprenorphine for opioid use disorder treatment in an outpatient setting: a case series. J Addict Med Sep-Oct. 2022;01(5):534\u201340. https:\/\/doi.org\/10.1097\/ADM.0000000000000961.","journal-title":"J Addict Med Sep-Oct"},{"issue":"4","key":"661_CR19","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1097\/ADM.0000000000001154","volume":"01","author":"M Noel","year":"2023","unstructured":"Noel M, Abbs E, Suen L, et al. The howard street method: a community pharmacy-led low dose overlap buprenorphine initiation protocol for individuals using fentanyl. J Addict Med Jul-Aug. 2023;01(4):e255\u201361. https:\/\/doi.org\/10.1097\/ADM.0000000000001154.","journal-title":"J Addict Med Jul-Aug"},{"key":"661_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"23","author":"S Michie","year":"2011","unstructured":"Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci Apr. 2011;23:6:42. https:\/\/doi.org\/10.1186\/1748-5908-6-42.","journal-title":"Implement Sci Apr"},{"key":"661_CR21","doi-asserted-by":"publisher","first-page":"209535","DOI":"10.1016\/j.josat.2024.209535","volume":"168","author":"MR Guido","year":"2025","unstructured":"Guido MR, Hauschild MH, Tookes HE, Bartholomew TS, Suarez E. Jr. Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey. J Subst Use Addict Treat Jan. 2025;168:209535. https:\/\/doi.org\/10.1016\/j.josat.2024.209535.","journal-title":"J Subst Use Addict Treat Jan"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00661-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00661-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T07:29:10Z","timestamp":1776151750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00661-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["661"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00661-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7160434\/v1","asserted-by":"object"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board at the University of Miami approved this study (20230483) and written informed consent was obtained from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from each participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}